Success Stories2021-03-10T17:54:12+00:00

MTEC member develops treatment for COVID-19 gastrointestinal symptoms

June 8th, 2021|Categories: Success Stories|Tags: , , |

A gastrointestinal targeted therapy could reduce overall viral burden, inhibit disease progression, accelerate viral clearance, and block significant transmission routes.

MCDC member receives DoD funding for Phase-2 trials of PUL-042 against COVID-19

June 4th, 2021|Categories: Success Stories|Tags: , , |

Pulmotect, Inc., a clinical-stage biotechnology company and non-traditional Medical CBRN Defense Consortium (MCDC) member, is joining the fight against COVID-19.

MTEC member researches treatment of septic shock, the cause of 70% of COVID deaths

May 26th, 2021|Categories: Success Stories|Tags: , , |

Vivacelle Bio, Inc., a non-traditional small business and Medical Technology Enterprise Consortium (MTEC) member, was awarded $5.3 million to research treatment of septic shock.

MTEC member developing novel engineered antibody that neutralizes coronaviruses

May 20th, 2021|Categories: Success Stories|Tags: , , |

With funding from the Medical Technology Enterprise Consortium (MTEC), Centivax is developing an optimized antibody therapeutic to treat, as well as protect against, COVID-19.

DAT supports event to test effective technology for military

May 4th, 2021|Categories: Success Stories|Tags: |

Earlier this month, the Demonstration and Assessment Team (DAT) supported four U.S. Navy partners at the Naval Integration in Contested Environments Advanced Naval Technology Exercise (NICE ANTX) during a 10-day event.

view all news
Go to Top